Introduction

This page provides a comprehensive analysis of the known insider trading history of L Daniel Browne. Insiders are officers, directors, or significant investors in a company. It is illegal for insiders to make trades in their companies based on specific, non-public information. This does not mean it is illegal for them to make any trades in their own companies. However, they must report all trades to the SEC via a Form 4. Despite these restrictions, academic research suggests that insiders - in general - tend to outperform the market in their own companies.

Average Trade Profitability

The average trade profitability is the average return of all the open market purchases made by the insider in the last three years. To calculate this, we examine every open-market, unplanned purchase made by the insider, excluding all trades that were marked as part of a 10b5-1 trading plan. We then calculate the average performance of those trades over 3, 6, and 12 months, averaging each of those durations to generate a final performance metric for each trade. Finally, we average all of the performance metrics to calculate a performance metric for the insider. This list only includes insiders that have made at least three trades in the last two years.

If this insiders trade profitability is "N/A", then the insider either has not made any open-market purchases in the last three years, or the trades they’ve made are too recent to calculate a reliable performance metric.

Update Frequency: Daily

See the list of most profitable insider traders.

Companies with Reported Insider Positions

The SEC filings indicate L Daniel Browne has reported holdings or trades in the following companies:

Security Title Latest Reported Holdings
US:RVNC / Revance Therapeutics, Inc. CEO and President, Director 152,193
How to Interpret the Charts

The following charts show the stock performance of securities subsequent to each open-market, non-planned trade made by L Daniel Browne. Non-planned trade are trades that were not made as part of a 10b5-1 trading plan. The stock performance is charted as cumulative percent change in share price. For example, if an insider trade was made on January 1, 2019, the chart will show the daily percent change of the security to the present day. If the share price were to go from $10 to $15 during this time, the cumulative percent change in share price would be 50%. A change in price from $10 to $20 would be 100%, and a change in price of $10 to $5 would be -50%.

Ultimately, we are trying to determine how closely the insider’s trades correlate to excess returns (positive or negative) in the share price in order to see if the insider is timing their trades to profit from insider information. Consider the situation where an insider was doing this. In this situation, we would expect either (a) positive returns after purchases, or (b) negative returns after sales. In the case of (a), the PURCHASE chart would show a series of upwardly sloping curves, indicating positive returns after each purchase transaction. In the case of (b), the SALE chart would show a series of downward sloping curves, indicating negative returns after each sale transaction.

However, this alone is not enough to draw conclusions. If, for example, the share price of the company was in a non-cyclical climb over many years, then we would expect all the post-purchase plots to be upwardly sloping. Likewise, non-cyclical declines over many years would result in downward sloping post-trade plots. Neither of these charts would suggest insider trading activity.

The strongest indicator would be a situation where the share price was extremely cyclical, and there were both positive signals in the PURCHASE chart and negative plots on the SALE chart. This situation would be highly suggestive of an insider that was timing trades to their financial advantage.

Insider Trading History

This table shows the complete list of insider trades made by L Daniel Browne as disclosed to the Securities Exchange Commission (SEC).

File Date Tran Date Form Ticker Security Code 10b5-1 Shares Remaining Shares Percent
Change
Share
Price
Tran
Value
Remaining
Value
2019-07-02 2019-06-28 4 RVNC Revance Therapeutics, Inc.
Common Stock
J - Other 1,000 152,193 0.66 11.02 11,024 1,677,852
2019-03-19 2019-03-18 4 RVNC Revance Therapeutics, Inc.
Common Stock
S - Sale X -11,613 151,193 -7.13 15.51 -180,068 2,344,353
2019-03-19 2019-03-15 4 RVNC Revance Therapeutics, Inc.
Common Stock
F - Taxes -2,881 162,806 -1.74 15.45 -44,511 2,515,353
2019-03-19 2019-03-15 4 RVNC Revance Therapeutics, Inc.
Common Stock
F - Taxes -3,256 165,687 -1.93 15.45 -50,305 2,559,864
2019-02-20 2019-02-19 4 RVNC Revance Therapeutics, Inc.
Common Stock
S - Sale X -5,446 168,943 -3.12 17.68 -96,285 2,986,912
2019-02-20 2019-02-15 4 RVNC Revance Therapeutics, Inc.
Common Stock
F - Taxes -3,154 174,389 -1.78 17.69 -55,794 3,084,941
2019-01-25 2019-01-24 4 RVNC Revance Therapeutics, Inc.
Employee Stock Option (Right to Buy)
A - Award 200,000 200,000
2019-01-25 2019-01-24 4 RVNC Revance Therapeutics, Inc.
Common Stock
A - Award 35,000 177,543 24.55
2018-07-03 2018-06-29 4 RVNC Revance Therapeutics, Inc.
Common Stock
J - Other 668 142,543 0.47 23.33 15,586 3,325,885
2018-03-16 2018-03-16 4 RVNC Revance Therapeutics, Inc.
Common Stock
M - Exercise 20,000 0 -100.00
2018-03-16 2018-03-16 4 RVNC Revance Therapeutics, Inc.
Common Stock
S - Sale X -5,452 141,875 -3.70 31.43 -171,348 4,458,904
2018-03-16 2018-03-16 4 RVNC Revance Therapeutics, Inc.
Common Stock
M - Exercise 20,000 147,327 15.71 2.55 51,000 375,684
2018-03-16 2018-03-15 4 RVNC Revance Therapeutics, Inc.
Common Stock
F - Taxes -2,881 127,327 -2.21 31.65 -91,184 4,029,900
2018-03-16 2018-03-15 4 RVNC Revance Therapeutics, Inc.
Common Stock
S - Sale X -1,000 130,208 -0.76 32.80 -32,800 4,270,822
2018-03-09 2018-03-07 4 RVNC Revance Therapeutics, Inc.
Common Stock
S - Sale X -27,283 131,208 -17.21 31.43 -857,505 4,123,867
2018-02-16 2018-02-15 4 RVNC Revance Therapeutics, Inc.
Common Stock
F - Taxes -3,074 158,491 -1.90 31.75 -97,600 5,032,089
2018-02-09 2018-02-08 4 RVNC Revance Therapeutics, Inc.
Employee Stock Option (Right to Buy)
A - Award 169,000 169,000
2018-02-09 2018-02-08 4 RVNC Revance Therapeutics, Inc.
Common Stock
A - Award 28,250 161,565 21.19
2018-01-03 2017-12-29 4 RVNC Revance Therapeutics, Inc.
Common Stock
J - Other 127 133,315 0.10 22.99 2,920 3,065,245
2017-11-24 2017-11-22 4 RVNC Revance Therapeutics, Inc.
Common Stock
S - Sale X -7,600 133,188 -5.40 24.94 -189,570 3,322,162
2017-10-20 2017-10-18 4 RVNC Revance Therapeutics, Inc.
Common Stock
S - Sale X -7,662 140,788 -5.16 26.16 -200,405 3,682,409
2017-09-22 2017-09-20 4 RVNC Revance Therapeutics, Inc.
Common Stock
S - Sale X -7,600 148,450 -4.87 23.58 -179,185 3,500,006
2017-08-25 2017-08-23 4 RVNC Revance Therapeutics, Inc.
Stock Option (Right to Buy)
M - Exercise -331 10,990 -2.92
2017-08-25 2017-08-23 4 RVNC Revance Therapeutics, Inc.
Common Stock
S - Sale X -22,800 156,050 -12.75 22.76 -519,031 3,552,400
2017-08-25 2017-08-23 4 RVNC Revance Therapeutics, Inc.
Common Stock
M - Exercise 331 178,850 0.19 2.55 844 456,068
2017-07-05 2017-06-30 4 RVNC Revance Therapeutics, Inc.
Common Stock
J - Other 1,000 178,519 0.56 18.32 18,318 3,270,022
2017-06-14 2017-06-12 4 RVNC Revance Therapeutics, Inc.
Stock Option (Right to Buy)
M - Exercise -8,300 11,321 -42.30
2017-06-14 2017-06-12 4 RVNC Revance Therapeutics, Inc.
Common Stock
M - Exercise 8,300 177,519 4.90 2.55 21,165 452,673
2017-05-31 2017-05-30 4 RVNC Revance Therapeutics, Inc.
Stock Option (Right to Buy)
M - Exercise -5,000 19,621 -20.31
2017-05-31 2017-05-30 4 RVNC Revance Therapeutics, Inc.
Common Stock
M - Exercise 5,000 169,219 3.04 2.55 12,750 431,508
2017-05-24 2017-05-24 4 RVNC Revance Therapeutics, Inc.
Common Stock
S - Sale X -19,713 164,219 -10.72 20.35 -401,091 3,341,282
2017-05-24 2017-05-22 4 RVNC Revance Therapeutics, Inc.
Common Stock
S - Sale X -12,287 183,932 -6.26 20.20 -248,159 3,714,856
2017-03-17 2017-03-16 4 RVNC Revance Therapeutics, Inc.
Common Stock
F - Taxes -3,171 196,219 -1.59 19.20 -60,885 3,767,542
2017-02-24 2017-02-22 4 RVNC Revance Therapeutics, Inc.
Common Stock
S - Sale X -1,269 199,390 -0.63 20.70 -26,263 4,126,595
2017-02-24 2017-02-22 4 RVNC Revance Therapeutics, Inc.
Common Stock
S - Sale X -9,768 200,659 -4.64 20.56 -200,787 4,124,666
2017-01-30 2017-01-26 4 RVNC Revance Therapeutics, Inc.
Employee Stock Option (Right to Buy)
A - Award 155,000 155,000
2017-01-30 2017-01-26 4 RVNC Revance Therapeutics, Inc.
Common Stock
A - Award 25,800 210,427 13.97
2017-01-27 2017-01-25 4 RVNC Revance Therapeutics, Inc.
Common Stock
S - Sale X -12,000 184,627 -6.10 19.78 -237,398 3,652,513
2017-01-03 2016-12-30 4 RVNC Revance Therapeutics, Inc.
Common Stock
J - Other 1,000 196,627 0.51 11.58 11,577 2,276,351
2016-12-30 2016-12-28 4 RVNC Revance Therapeutics, Inc.
Common Stock
S - Sale X -12,000 195,627 -5.78 20.94 -251,250 4,095,940
2016-11-25 2016-11-25 4 RVNC Revance Therapeutics, Inc.
Common Stock
S - Sale X -822 207,627 -0.39 18.70 -15,371 3,882,625
2016-11-25 2016-11-25 4 RVNC Revance Therapeutics, Inc.
Common Stock
S - Sale X -11,178 208,449 -5.09 17.86 -199,633 3,722,795
2016-10-28 2016-10-26 4 RVNC Revance Therapeutics, Inc.
Common Stock
S - Sale X -12,000 219,627 -5.18 14.85 -178,199 3,261,439
2016-05-23 2016-05-19 4 RVNC Revance Therapeutics, Inc.
Common Stock
F - Taxes -12,050 231,627 -4.95 17.11 -206,176 3,963,138
2016-02-11 2016-02-09 4 RVNC Revance Therapeutics, Inc.
Employee Stock Option (Right to Buy)
A - Award 175,000 175,000
2016-02-11 2016-02-09 4 RVNC Revance Therapeutics, Inc.
Common Stock
A - Award 25,000 243,677 11.43
2016-01-04 2015-12-31 4 RVNC Revance Therapeutics, Inc.
Common Stock
J - Other 262 218,677 0.12 27.00 7,074 5,904,279
2016-01-04 2015-12-30 4 RVNC Revance Therapeutics, Inc.
Stock Option (right to buy)
M - Exercise -12,045 24,621 -32.85
2016-01-04 2015-12-30 4 RVNC Revance Therapeutics, Inc.
Common Stock
M - Exercise 12,045 218,415 5.84 2.55 30,715 556,958
2015-07-02 2015-06-30 4 RVNC Revance Therapeutics, Inc.
Common Stock
J - Other 1,000 1,000 14.16 14,160 14,160
2015-05-21 2015-05-19 4 RVNC Revance Therapeutics, Inc.
Common Stock
F - Taxes -12,025 205,101 -5.54 25.94 -311,928 5,320,320
2015-01-30 2015-01-28 4 RVNC Revance Therapeutics, Inc.
Stock Option (right to buy)
A - Award 246,500 246,500
2015-01-30 2015-01-28 4 RVNC Revance Therapeutics, Inc.
Common Stock
A - Award 43,500 217,126 25.05
2014-12-01 2014-11-28 4 RVNC Revance Therapeutics, Inc.
Common Stock
P - Purchase 6,000 172,626 3.60 16.67 100,019 2,877,658
2014-05-21 2014-05-19 4 RVNC Revance Therapeutics, Inc.
Stock Option (Right to Buy)
A - Award 295,800 295,800
2014-05-21 2014-05-19 4 RVNC Revance Therapeutics, Inc.
Common Stock
A - Award 96,000 166,626 135.93 32.22 3,093,120 5,368,690
2014-02-11 2014-02-11 4 RVNC Revance Therapeutics, Inc.
Series E-2 Convertible Preferred Stock
C - Conversion -409 0 -100.00
2014-02-11 2014-02-11 4 RVNC Revance Therapeutics, Inc.
Series E-1 Convertible Preferred Stock
C - Conversion -17,293 0 -100.00
2014-02-11 2014-02-11 4 RVNC Revance Therapeutics, Inc.
Common Stock
C - Conversion 17,702 71,035 33.19
2014-02-11 2013-12-17 4 RVNC Revance Therapeutics, Inc.
Stock Option (Right to Buy)
A - Award 99,583 99,583
2014-02-05 3 RVNC Revance Therapeutics, Inc.
Common Stock
106,666
2014-02-05 3 RVNC Revance Therapeutics, Inc.
Common Stock
106,666
P
Open market or private purchase of non-derivative or derivative security
S
Open market or private sale of non-derivative or derivative security
A
Grant, award, or other acquisition of securities from the company (such as an option)
C
Conversion of derivative
D
Sale or transfer of securities back to the company
F
Payment of exercise price or tax liability using portion of securities received from the company
G
Gift of securities by or to the insider
K
Equity swaps and similar hedging transactions
M
Exercise or conversion of derivative security received from the company (such as an option)
V
A transaction voluntarily reported on Form 4
J
Other (accompanied by a footnote describing the transaction)